Agilent Technologies, Inc. (A) Expected to Earn Q4 2017 Earnings of $0.62 Per Share
Agilent Technologies, Inc. (NYSE:A) – Investment analysts at Jefferies Group boosted their Q4 2017 earnings estimates for Agilent Technologies in a report issued on Tuesday. Jefferies Group analyst B. Couillard now expects that the medical research company will post earnings of $0.62 per share for the quarter, up from their previous forecast of $0.58. Jefferies Group currently has a “Buy” rating and a $66.00 price target on the stock. Jefferies Group also issued estimates for Agilent Technologies’ Q4 2018 earnings at $0.66 EPS.
Other analysts have also recently issued reports about the stock. Wells Fargo & Company upgraded shares of Agilent Technologies from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $42.92 to $60.73 in a research note on Wednesday, July 12th. BidaskClub upgraded shares of Agilent Technologies from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. Deutsche Bank AG set a $68.00 target price on shares of Agilent Technologies and gave the stock a “buy” rating in a research note on Wednesday. Robert W. Baird lifted their target price on shares of Agilent Technologies from $57.00 to $62.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 24th. Finally, J P Morgan Chase & Co reiterated an “overweight” rating and issued a $70.00 target price on shares of Agilent Technologies in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Agilent Technologies currently has an average rating of “Buy” and a consensus target price of $62.55.
ILLEGAL ACTIVITY WARNING: “Agilent Technologies, Inc. (A) Expected to Earn Q4 2017 Earnings of $0.62 Per Share” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/08/18/agilent-technologies-inc-a-expected-to-earn-q4-2017-earnings-of-0-62-per-share.html.
Agilent Technologies (NYSE A) opened at 60.86 on Friday. The stock has a market capitalization of $19.60 billion, a PE ratio of 31.39 and a beta of 1.30. The stock’s 50 day moving average is $60.23 and its 200 day moving average is $56.04. Agilent Technologies has a 12-month low of $42.92 and a 12-month high of $62.42.
Agilent Technologies (NYSE:A) last released its quarterly earnings data on Tuesday, August 15th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.52 by $0.07. Agilent Technologies had a net margin of 14.36% and a return on equity of 16.95%. The firm had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the previous year, the company earned $0.49 earnings per share. The firm’s quarterly revenue was up 6.7% on a year-over-year basis.
In other news, insider Dominique Grau sold 13,007 shares of Agilent Technologies stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $62.00, for a total transaction of $806,434.00. Following the completion of the transaction, the insider now directly owns 60,098 shares of the company’s stock, valued at approximately $3,726,076. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Patrick Kaltenbach sold 2,074 shares of Agilent Technologies stock in a transaction that occurred on Wednesday, May 31st. The shares were sold at an average price of $60.43, for a total transaction of $125,331.82. Following the transaction, the insider now directly owns 42,212 shares of the company’s stock, valued at $2,550,871.16. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 125,615 shares of company stock valued at $7,543,943.
Several institutional investors have recently bought and sold shares of A. Creative Planning raised its stake in shares of Agilent Technologies by 6.3% in the first quarter. Creative Planning now owns 11,961 shares of the medical research company’s stock valued at $632,000 after buying an additional 710 shares during the last quarter. Capstone Asset Management Co. raised its stake in shares of Agilent Technologies by 7.4% in the first quarter. Capstone Asset Management Co. now owns 43,126 shares of the medical research company’s stock valued at $2,280,000 after buying an additional 2,990 shares during the last quarter. DnB Asset Management AS raised its stake in shares of Agilent Technologies by 14.1% in the first quarter. DnB Asset Management AS now owns 40,449 shares of the medical research company’s stock valued at $2,139,000 after buying an additional 5,000 shares during the last quarter. Coastline Trust Co bought a new stake in shares of Agilent Technologies during the first quarter valued at approximately $277,000. Finally, Boston Advisors LLC raised its stake in shares of Agilent Technologies by 27.7% in the first quarter. Boston Advisors LLC now owns 40,302 shares of the medical research company’s stock valued at $2,131,000 after buying an additional 8,730 shares during the last quarter.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.